BERKELEY, Calif., April 4, 2012 /PRNewswire/ -- Hagens Berman today reminded investors that less than two weeks remain before the lead plaintiff deadline in a securities class-action lawsuit filed against Metabolix, Inc. (NASDAQ: MBLX) ("MBLX"). Investors who purchased shares of MBLX common stock between March 10, 2010, and Jan. 12, 2012 (the "class period"), have losses greater than $100,000 and desire to be a lead representative plaintiff, can also contact the firm for a consultation. The deadline to move the court for lead plaintiff status is April 17, 2012. Investors can reach Partner Reed Kathrein, who is leading the firm's investigation, by calling (510) 725-3000. They can also contact Mr. Kathrein online by sending an email to MBLX@hbsslaw.com or by visiting www.hbsslaw.com/MBLX. MBLX partnered with Archer-Daniels-Midland to produce plastics under the brand name Mirel. However, on Jan. 12, 2012, MBLX announced that ADM had given notice it would be ending the partnership. The securities class-action lawsuit was filed in the United States District Court for the District of Massachusetts. The complaint claims that MBLX misled investors regarding the company's financial performance. Specifically, it alleges that MBLX knew that Mirel was not commercially viable, but failed to disclose this to investors. Following MBLX's announcement that ADM was ending the partnership, MBLX shares dropped more than 50 percent to $2.54. Hagens Berman is investigating whether MBLX management had warning about ADM's decision or knew that Mirel was not commercially viable. Whistleblowers Persons with knowledge that may help the investigation are also encouraged to contact the firm. The SEC recently finalized new rules as part of its implementation of the whistleblower provisions in the Dodd-Frank Wall Street Reform Bill. The new rules protect whistleblowers from employer retaliation and allow the SEC to reward those who provide information leading to a successful enforcement with up to 30 percent of the recovery.